SUPRIYA LIFESCIENCE ALL AROUND SET TO TAP PHARMA API OPPORTUNITY: MOTILAL OSWAL FINANCIAL SERVICES' SNEHA PODDAR
"We
like Supriya Lifescience for its specialty item portfolio, in reverse
incorporated plan of action and hearty financials. It is very much positioned
to tap the chance in the pharma API market given its solid pipeline zeroed in
on additional broadening," said Sneha Poddar, AVP-Retail Research at
Motilal Oswal Financial Services.
"Supriya
Lifescience has a specialty item arrangement of 38 APIs with center basically
around different restorative regions. It has reliably been India's biggest
exporter of specific specialty items with an even presence among managed and
semi/non-directed business sectors," she said.
Supriya
Lifescience shares were at Rs 401.4 each on BSE and Rs 400.7 each on NSE around
early afternoon. That denoted a premium of in excess of 46% over the issue cost
of Rs 274. (Peruse more on Supriya Lifescience shares)
Comments
Post a Comment